Background/Aims: In podocytes, the overexpression of TGFβ ligands and receptors during glomerulosclerosis could be a causal factor for injury induction and perpetuation in glomerular tufts. Mitochondrial dysfunction and oxidative stress are emerging as potential therapeutic targets in glomerular injury, and TGFβ has been shown to modulate mitochondrial metabolism in different cell types. This study aims at investigating the role of TGFβ in podocyte energy metabolism and cytoskeleton dynamics. Methods: Mitochondrial function and cytoskeleton dynamics were analyzed in TGFβ-treated WT and Smad2/3 double KO podocytes. Results: TGFβ treatment in podocytes induced a significant Smad-dependent increase of mitochondrial oxygen consumption rate (OCR). ATP content was unchanged and increased respiration was not associated with increased mitochondrial mass. Increased cellular reactive oxygen species induced by Smad-mediated TGFβ signaling were reverted by NADPH oxidase inhibitor apocynin. TGFβ treatment did not induce mitochondrial oxidative stress, and Smad2/3-dependent TGFβ signaling and increased mitochondrial OCR were found to be associated with actin cytoskeleton dynamics. The role of motor proteins myosin II and dynamin in TGFβ-induced actin polymerization was demonstrated by specific inhibition, resulting in actin stabilization and normalization of mitochondrial OCR. Conclusion: TGFβ-induced rearrangements of actin cytoskeleton are controlled by Smad2/3 signaling pathways and coupled with the activation of mitochondrial ATP synthesis as bioenergetic adaptation to ATP consumption by ATP- and GTP-dependent motor proteins, myosin II and dynamin.

Keywords:
Mitochondria, Cytoskeleton, TGFβ, Podocyte
1.
Massagué J: TGFβ signalling in context. Nat Rev Mol Cell Biol 2012;13:616-630.
2.
Böttinger EP: TGF-beta in renal injury and disease. Semin Nephrol 2007;27:309-320.
3.
Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, Wen P, Yang J: The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 2012;302:F369-F379.
4.
Casalena G, Daehn I, Bottinger E: Transforming growth factor-β, bioenergetics, and mitochondria in renal disease. Semin Nephrol 2012;32:295-303.
5.
Greka A, Mundel P: Cell biology and pathology of podocytes. Annu Rev Physiol 2012;74:299-323.
6.
Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G: Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002;161:2179-2193.
7.
Kim JH, Kim BK, Moon KC, Hong HK, Lee HS: Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003;64:1715-1721.
8.
Che R, Yuan Y, Huang S, Zhang A: Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol 2014;306:F367-F378.
9.
Müller-Deile J, Schiffer M: The podocyte power-plant disaster and its contribution to glomerulopathy. Front Endocrinol (Lausanne) 2014;5:209.
10.
Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Böttinger EP: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001;108:807-816.
11.
Xavier S, Niranjan T, Krick S, Zhang T, Ju W, Shaw AS, Schiffer M, Böttinger EP: TbetaRI independently activates Smad- and CD2AP-dependent pathways in podocytes. J Am Soc Nephrol 2009;20:2127-2137.
12.
Das R, Xu S, Quan X, Nguyen TT, Kong ID, Chung CH, Lee EY, Cha SK, Park KS: Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am J Physiol Renal Physiol 2014;306:F155-F167.
13.
Daehn I, Casalena G, Zhang T, Shi S, Fenninger F, Barasch N, Yu L, D'Agati V, Schlondorff D, Kriz W, Haraldsson B, Bottinger EP: Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014;124:1608-1621.
14.
Wu DT, Bitzer M, Ju W, Mundel P, Böttinger EP: TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005;16:3211-3221.
15.
Soda K, Balkin DM, Ferguson SM, Paradise S, Milosevic I, Giovedi S, Volpicelli-Daley L, Tian X, Wu Y, Ma H, Son SH, Zheng R, Moeckel G, Cremona O, Holzman LB, De Camilli P, Ishibe S: Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. J Clin Invest 2012;122:4401-4411.
16.
Chase SE, Encina CV, Stolzenburg LR, Tatum AH, Holzman LB, Krendel M: Podocyte-specific knockout of myosin 1e disrupts glomerular filtration. Am J Physiol Renal Physiol 2012;303:F1099-F1106.
17.
Babayeva S, Miller M, Zilber Y, El Kares R, Bernard C, Bitzan M, Goodyer P, Torban E: Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes. Pediatr Nephrol 2011;26:1071-1081.
18.
Sever S, Altintas MM, Nankoe SR, Möller CC, Ko D, Wei C, Henderson J, del Re EC, Hsing L, Erickson A, Cohen CD, Kretzler M, Kerjaschki D, Rudensky A, Nikolic B, Reiser J: Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 2007;117:2095-2104.
19.
Stieger N, Worthmann K, Teng B, Engeli S, Das AM, Haller H, Schiffer M: Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes. Metabolism 2012;61:1073-1086.
20.
Abe Y, Sakairi T, Beeson C, Kopp JB: TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. Am J Physiol Renal Physiol 2013;305:F1477-F1490.
21.
Greka A, Mundel P: Calcium regulates podocyte actin dynamics. Semin Nephrol 2012;32:319-326.
22.
Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P: Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007;17:428-437.
23.
Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-938.
24.
Krendel M, Kim SV, Willinger T, Wang T, Kashgarian M, Flavell RA, Mooseker MS: Disruption of myosin 1e promotes podocyte injury. J Am Soc Nephrol 2009;20:86-94.
25.
Beck H, Flynn K, Lindenberg KS, Schwarz H, Bradke F, Di Giovanni S, Knöll B: Serum response factor (SRF)-cofilin-actin signaling axis modulates mitochondrial dynamics. Proc Natl Acad Sci U S A 2012;109:E2523-E2532.
26.
Teng B, Lukasz A, Schiffer M: The ADF/cofilin-pathway and actin dynamics in podocyte injury. Int J Cell Biol 2012;2012:320531.
27.
Garg P, Verma R, Cook L, Soofi A, Venkatareddy M, George B, Mizuno K, Gurniak C, Witke W, Holzman LB: Actin-depolymerizing factor cofilin-1 is necessary in maintaining mature podocyte architecture. J Biol Chem 2010;285:22676-22688.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.